Does Crovalimab Interact with Eculizumab?
CDI records a major classification for Crovalimab and Eculizumab. The stored summary is: Formation of dual targeting drug complexes (DTDCs) when switching between crovalimab and eculizumab can result in Type III hypersensitivity reactions. DTDCs expected to clear within approximately 8 weeks. The mechanism involves crovalimab and eculizumab bind different epitopes on c5, forming dtdcs that may trigger type iii hypersensitivity reactions. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Major
- Crovalimab Class
- Complement C5 Inhibitor
- Eculizumab Class
- Complement Inhibitor
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Crovalimab and eculizumab bind different epitopes on C5, forming DTDCs that may trigger Type III hypersensitivity reactions
What To Tell Your Doctor or Pharmacist
If you are taking Crovalimab and your doctor is considering prescribing Eculizumab (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider